CYBA and chronic kidney disease: In tolvaptan-treated ADPKD patients, the reduction in p22phox protein levels not only suggests reduced OxSt, but also, given its presence in leukocytes, an inhibition of leukocyte activation, a well-known cause of OxSt in CKD.